Xencor (XNCR) Competitors $10.33 -0.14 (-1.34%) Closing price 04:00 PM EasternExtended Trading$10.33 0.00 (0.00%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XNCR vs. APLS, VKTX, MOR, XENE, CGON, OGN, RARE, GMTX, KNSA, and MLYSShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Apellis Pharmaceuticals (APLS), Viking Therapeutics (VKTX), MorphoSys (MOR), Xenon Pharmaceuticals (XENE), CG Oncology (CGON), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), Gemini Therapeutics (GMTX), Kiniksa Pharmaceuticals International (KNSA), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Xencor vs. Its Competitors Apellis Pharmaceuticals Viking Therapeutics MorphoSys Xenon Pharmaceuticals CG Oncology Organon & Co. Ultragenyx Pharmaceutical Gemini Therapeutics Kiniksa Pharmaceuticals International Mineralys Therapeutics Apellis Pharmaceuticals (NASDAQ:APLS) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Does the media favor APLS or XNCR? In the previous week, Apellis Pharmaceuticals had 3 more articles in the media than Xencor. MarketBeat recorded 10 mentions for Apellis Pharmaceuticals and 7 mentions for Xencor. Xencor's average media sentiment score of 0.94 beat Apellis Pharmaceuticals' score of 0.20 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apellis Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xencor 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, APLS or XNCR? Apellis Pharmaceuticals has higher revenue and earnings than Xencor. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApellis Pharmaceuticals$781.37M3.59-$197.88M-$1.82-12.21Xencor$110.49M6.67-$232.62M-$2.40-4.30 Do analysts rate APLS or XNCR? Apellis Pharmaceuticals presently has a consensus target price of $34.12, suggesting a potential upside of 53.54%. Xencor has a consensus target price of $22.25, suggesting a potential upside of 115.39%. Given Xencor's stronger consensus rating and higher possible upside, analysts clearly believe Xencor is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.58Xencor 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders and institutionals hold more shares of APLS or XNCR? 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 6.5% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Xencor shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, APLS or XNCR? Apellis Pharmaceuticals has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Is APLS or XNCR more profitable? Apellis Pharmaceuticals has a net margin of -30.24% compared to Xencor's net margin of -121.52%. Xencor's return on equity of -25.75% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Apellis Pharmaceuticals-30.24% -116.09% -26.72% Xencor -121.52%-25.75%-18.19% SummaryApellis Pharmaceuticals beats Xencor on 9 of the 17 factors compared between the two stocks. Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$746.75M$2.55B$5.75B$10.39BDividend YieldN/A57.80%5.77%4.64%P/E Ratio-4.305.4957.3222.37Price / Sales6.67716.05544.74124.93Price / CashN/A176.2437.5461.24Price / Book1.075.1412.876.30Net Income-$232.62M$32.95M$3.29B$271.03M7 Day Performance2.99%0.09%-0.26%-0.15%1 Month Performance28.96%5.04%3.84%6.41%1 Year Performance-47.72%1.02%68.35%28.81% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor3.4994 of 5 stars$10.33-1.3%$22.25+115.4%-48.2%$746.75M$110.49M-4.30280APLSApellis Pharmaceuticals4.0932 of 5 stars$23.49+2.1%$34.12+45.2%-26.0%$2.91B$781.37M-12.91770VKTXViking Therapeutics4.3077 of 5 stars$26.25+3.3%$90.38+244.3%-57.0%$2.86BN/A-17.1620Analyst ForecastMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730XENEXenon Pharmaceuticals2.4942 of 5 stars$37.40+1.2%$53.30+42.5%-6.0%$2.85B$9.43M-10.54210Positive NewsCGONCG Oncology2.4599 of 5 stars$37.04+0.4%$56.00+51.2%+0.4%$2.81B$1.14M-20.9361Insider TradeGap UpOGNOrganon & Co.4.4748 of 5 stars$10.58+1.2%$17.33+63.9%-47.1%$2.72B$6.40B3.934,000Positive NewsRAREUltragenyx Pharmaceutical4.1877 of 5 stars$29.47+4.8%$81.50+176.6%-50.0%$2.71B$560.23M-5.331,294GMTXGemini TherapeuticsN/A$60.79-2.9%N/A+32.4%$2.63BN/A-60.7930High Trading VolumeKNSAKiniksa Pharmaceuticals International2.9259 of 5 stars$36.08+1.9%$41.17+14.1%+47.6%$2.62B$423.24M902.23220Positive NewsAnalyst ForecastMLYSMineralys Therapeutics2.714 of 5 stars$38.78-1.2%$43.50+12.2%+232.2%$2.60BN/A-10.8928Positive News Related Companies and Tools Related Companies Apellis Pharmaceuticals Alternatives Viking Therapeutics Alternatives MorphoSys Alternatives Xenon Pharmaceuticals Alternatives CG Oncology Alternatives Organon & Co. Alternatives Ultragenyx Pharmaceutical Alternatives Gemini Therapeutics Alternatives Kiniksa Pharmaceuticals International Alternatives Mineralys Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XNCR) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XNCR Stock Alerts